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Abstract 
Osteoporosis is a systemic skeletal disease leading to increased risk of fragility fractures. These 
fractures lead to significant patient morbidity, increased mortality and substantial health and 
social care costs.  
The use of stem cells for cell-based therapies is currently an exciting, promising and growing 
area for disease treatment and regenerative medicine. However, the attitudes of participants 
towards the use of stem cells for regenerative medicine applications, particularly for therapeutic 
interventions amongst the older population, have not been well explored. 
This study explored patient perceptions of a proposed new treatment utilising a novel 
orthobiologic stem cell therapy. An online questionnaire for participants affected by 
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osteoporosis was designed using the ‘Bristol Online Survey’ tool. In addition, three focus 
groups were held to explore a number of the issues raised by the findings in more depth. 
Findings showed that acceptability for the new treatment was high, as current treatments were 
variable in their effectiveness and new treatments were keenly welcomed. Participants 
indicated a willingness to have the proposed treatment in order to reduce their chance of 
experiencing a fracture, regardless of whether the treatment would reduce existing pain, or 
improve existing quality of life. The use of both autologous and allogeneic stem cells was 
acceptable, with slight differences in opinion indicating reservations regarding the potentially 
painful nature of stem cell extraction and allogeneic stem cell rejection.  
The findings demonstrated a clear mandate to the research team (and community) to continue 
their efforts in developing stem cell-based treatments for bone repair applications. 
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Introduction 
Osteoporosis is a systemic skeletal disease leading to increased risk of fragility fractures. These 
fractures lead to significant patient morbidity, increased mortality and substantial health and 
social care costs. Between 2015 and 2030, the number of participants in the world aged 60 
years or over is projected to grow by 56%, from 901 million to 1.4 billion, and by 2050, the 
global population of older persons is projected to more than double, reaching nearly 2.1 billion. 
Globally, the number of participants aged 80 years or over, i.e., the “oldest-old” persons, is 
growing even faster than the number of older participants overall. Projections indicate that by 
2050, participants over 80 will number 434 million, which has more than tripled since 2015 
(when there were 125 million participants over age 80) [1]. 
Medical advances have led to this welcome increase in life expectancy. However, life 
expectancy has increased by more years than healthy life expectancy and therefore the number 
of years lived in poor health have also increased [2]. As such, new medical advances are 
working towards continuing to ensure that more years are spent in good health.  
Osteoporosis is a disease which significantly affects healthy life expectancy, causing severe 
pain and disability to individual sufferers. It is described by the World Health Organization 
(WHO) as a “progressive systemic skeletal disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and 
susceptibility to fracture” [3]. Estimates of the worldwide prevalence and disability associated 
with osteoporotic fractures suggest that the burden of the disease compared to other disease 
states, using DALYs as a measure, (i.e., Disability-Adjusted Life Years which utilise number 
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of years lost due to ill-health, disability or early death) is second only to lung conditions [4]. In 
Europe, osteoporosis accounts for more DALYs than many non-communicable diseases 
including rheumatoid arthritis, Parkinson’s disease, breast cancer and prostate cancer [4]. 
In the UK, approximately 536,000 new fragility fractures occur each year, comprising 79,000 
hip fractures, 66,000 clinically diagnosed vertebral fractures, 69,000 forearm fractures and 
322,000 other fractures [5]. Such fractures are estimated to cost the National Health Service 
(NHS) over £4.4 billion, each year (estimated for 2010). Hip fractures account for around 50% 
of the total cost of fractures to the UK annually [5]. Approximately 53% of patients suffering 
a hip fracture can no longer live independently and 28.7% die within 12 months of the fracture. 
Only 54% of individuals admitted from home with a hip fracture return there within 30 days 
[5-8]. More than one-third of adult women and one in five men will sustain one or more fragility 
fractures in their lifetime [9]. For women, it is reported that the risk of hip fracture is higher 
than the risk of breast, ovarian and uterine cancer combined, while for men, the risk is higher 
than the risk for prostate cancer [10]. The risk of sustaining a fracture increases with age. This 
is due to decreasing bone mass, and the increased likelihood of falling among the elderly. It is 
estimated that the ageing of the UK population will lead to a doubling in the number of 
osteoporotic fractures over the next 50 years if there are no changes made to current treatment 
protocols [5]. 
Treatment options for patients with a diagnosis of osteoporosis include Bisphosphonates in 
tablet or injectable form, Parathyroid hormone (teriparatide) (given by injection), Hormone 
Replacement Therapy (HRT), Testosterone Treatment, Vitamin D or Calcium supplements [9]. 
However, long-term use of bisphosphonates has raised concerns in regard to atypical 
subtrochanteric fractures of the femur [11]. However, to address future healthcare demands 
research groups are heavily focused on regenerative medicine approaches (i.e., bone tissue 
regeneration) as a solution for long-term orthopaedic repair which could offer significant 
clinical and financial gains, whilst reducing trauma to the patient. Therapeutic approaches 
using Mesenchymal Stem Cells (MSCs) are currently under investigation for several conditions 
including stroke, multiple sclerosis and diabetes amongst many others [12,13]. In recent years, 
exploration in the use of MSCs for orthopaedic applications has increased dramatically [14].  
Orthobiologic therapy is a rapidly advancing field, which utilises cell-based therapies and 
biomaterials to promote bone healing and offers exciting alternatives to traditional treatment 
options for improving the long-term health of patients suffering from disabling musculoskeletal 
disorders [14,15]. Although human MSCs in bone marrow are known to decrease with age, 
MSCs can be expanded under culture conditions and expanded MSCs from older patients can 
retain effective osteogenic differentiation capacity [16]. A study by Sanghani-Kerai et al., 
explored the difference of characteristics between Mesenchymal Stem Cells (MSCs) harvested 
from young, adult, and ovariectomized rats and found that cells derived from osteopenic rats 
demonstrated reduced migrative capacity to stromal cell-derived factor 1. It was suggested that 
poor bone formation in postmenopausal women could be due to poor retention and function of 
mesenchymal stem cells resulting in delayed unions [17].  
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Although the stem cell source (i.e., autologous vs allogeneic) for these applications both have 
advantages and disadvantages, it is suggested that treatment decisions should be based on the 
age of the patient. For example, the allogeneic stem cell route would be the preferred choice 
for the very elderly patients, due to the fact that the quantity and quality of autologous stem 
cells from these patients would be very low, which would not justify inflicting further trauma 
to the patient by conducting an iliac crest aspiration. However, allogeneic cell-based therapies 
come with a view that they may elicit an immune reaction. 
The use of stem cells for cell-based therapies is currently an exciting, promising and growing 
area for disease treatment and regenerative medicine. Furthermore, the ability to develop 
unique biomaterials which could harness the cells potential would also offer significant 
therapeutic potential. Recent Studies have shown that synthetic materials can not only influence 
but can also induce, lineage-specific stem cell differentiation. Studies have shown that ions 
(such as calcium, magnesium and strontium etc.) if released from dissolving inorganic minerals 
at the desired rates could influence stem cell phenotype [18]. One study showed that controlled 
release of calcium and phosphate ions could influence osteogenic differentiation through 
mechanisms involving c-Fos and adenosine signalling. Studies have also shown that it is 
possible to use materials to harness cell-secreted factors to amplify stem cell expansion and 
differentiation [18]. 
Public opinion on the use of stem cells in research has been well explored and remains a 
contentious topic globally, though research into poll trends suggests that in the US at least, an 
increasing proportion of the population support government funding for embryonic stem cell 
research and view such research as morally acceptable [19-22]. What is less well explored are 
the attitudes of participants towards the use of stem cells for regenerative medicine 
applications, particularly for therapeutic interventions amongst the older population.  
A research team based at the University of Nottingham are developing an orthobiologic based 
material and stem cell therapy based prophylactic treatment for the prevention of fractures in 
participants with osteoporosis. This potential treatment could revolutionise treatments options 
for osteoporotic patients, especially for those considered to be at high risk of bone fracture 
[23,24]. 
However, patient perspectives on stem cell therapy related treatment options for this group of 
participants have not been explored before. This Patient and Public Involvement study was 
therefore established to explore patient perspectives of the orthobiologic technology proposed 
and to ascertain patient perceptions on the use of stem cells for the fracture prevention bone 
regeneration treatment proposed. 
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Materials and Methods 
Design and Distribution of Questionnaires 
An online questionnaire (Q1) for participants affected by osteoporosis was designed using the 
‘Bristol Online Survey’ tool and piloted by members of the study’s Patient and Public 
Involvement Reference Group to ensure it would be acceptable and understandable to the target 
audience. A postal version of the questionnaire was also available in addition to the electronic 
version of the questionnaire in order to address potential internet access issues likely to be 
experienced by the demographic of the target audience. Participants were also given the option 
of contacting the research team to request a paper version.  
A link to the questionnaire was also promoted by the Royal Osteoporosis Society (ROS - 
formerly known as the National Osteoporosis Society) via its regular communication channels. 
In addition, a significant number of paper versions were distributed via the ROS regional 
groups. A link to the questionnaire was also distributed to members of an existing patient group 
at the University of Birmingham known as the 1,000 Elders Group.  
Piloting of the questionnaire through the Reference Group took place during December 2016. 
The Questionnaire was launched on 13th Feb 2017 and remained open until 26th May 2017. 
The questionnaire comprised of 22 questions in total with the opportunity for participants to 
provide free text comments on the reasons for their responses to specific questions. Participants 
were advised it would take approximately 20 minutes to complete. A cover sheet provided 
outline information on the study whilst explanatory text throughout the questionnaire provided 
more detailed information on specific aspects of the proposed treatment. The questionnaire 
comprised of five sections as follows:  
• Background information on the participants’ experience of osteoporosis 
• Participants’ opinions on the acceptability of the proposed treatment 
• Participants’ opinions on the anticipated results and benefits of the proposed treatment 
• Participants’ opinions on other considerations such as the use of donor stem cells 
• Demographic information.  
A paper-only version of the questionnaire (Q2) was then adapted for use in outpatient clinics 
in University Hospital and Queen’s Medical Centre, Nottingham. The format remained broadly 
the same as in Q1, though a number of additional questions relating to the participants’ health 
status, were included in this version. 
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Focus Groups 
In addition to the questionnaire, three focus groups were held to explore a number of the issues 
raised by the findings in more depth. The demographic results from the questionnaires 
indicated that less than 2% participants who had completed the questionnaire were from a non-
white ethnic group, therefore participation for the focus groups was specifically targeted at 
members of non-white ethnic groups. An initial approach was made to a number of community 
groups in Birmingham, Leeds, Nottingham and Leicester. In all, eight groups were approached. 
These included faith groups, social groups such as lunch clubs and groups working with local 
communities to support health and education activities.  
The data from these focus groups were analysed thematically and the findings are presented 
separately to the quantitative data generated from the initial questionnaires 
 
Ethical Review 
The University’s ethical approval process was followed for the development and distribution 
of the first version of the questionnaire (Q1) through the ROS and 1,000 Elders Group and for 
the carrying out of the focus groups as these activities did not involve NHS patients in NHS 
settings. The distribution of the second version of the questionnaire (Q2) required full HRA 
ethical approval, as this component of the study involved NHS patients in NHS settings. 
 
Data Analysis  
The questionnaire was designed using the Bristol Online Survey tool which includes an 
analytical function to derive simple descriptive statistics.  
A thematic analysis of the qualitative data generated from the focus groups and free text 
responses to the questionnaire were subsequently carried out, guided by the principles of 
Ritchie and Spencer’s (1994) Framework Approach [25]. This involves the initial identification 
of analytical themes derived from the research questions, to which additional themes can be 
added as new insights emerge from the data. 
 
Results 
Demographic Responses 
In total, 421 responses were received from the questionnaires - 391 from Q1 and 30 from Q2. 
For Q1, 62% of participants reported having an official diagnosis of osteoporosis, whilst all 
participants from Q2 had an official diagnosis of osteoporosis, as would be expected from the 
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distribution mechanism. 91% of participants across both questionnaire versions were female. 
A good range of ages were represented by participants to both surveys (Fig. 1), though the age 
profiles differed slightly in that participants to Q1 had a slightly younger profile (42% of 
participants were below 60), whilst participants to Q2 had a slightly older age profile (43% of 
participants were aged over 70). 
 
Figure 1: A) Age range of participants to questions 1 and B) Age range of participants to Q2. 
 
Experience of Osteoporosis and Current Treatments 
There was almost equal representation amongst questionnaire participants between those 
diagnosed with osteoporosis within the last five years and those who had lived with a diagnosis 
of osteoporosis for more than five years (Fig. 2). The most common form of treatment for those 
with osteoporosis, was Vitamin D and Calcium supplements, with 47% and 40% of participants 
respectively taking these supplements. The next most common form of treatment was 
Bisphosphonate (drug) tablets, with 24% of participants taking these. The least common form 
of treatment was the Selective Oestrogen Receptor Modulator (SERM) with only two 
participants taking this treatment.  
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Free text responses in the questionnaires demonstrated that many participants were 
experiencing distressing side effects from their treatments and many were highly doubtful of 
its effectiveness. Many comments were provided that suggested individuals were highly 
enthusiastic for development of new treatments options.  
Just over half of participants with osteoporosis (52%) had a fracture due to osteoporosis. Of 
those, 6% of fractures experienced were hip fractures, whilst 31% of fractures reported were 
spinal and 28% were wrist fractures. 
 
Figure 2: Participants responses based on length of time from diagnosis. 
 
Acceptability of Treatment Responses 
Results regarding the acceptability of the proposed screening mechanisms and future treatment 
were positive. 94% of participants to Q1 were prepared to have a DEXA scan to assess 
eligibility for the treatment (this question related to participants to Q1 only, as the same 
question was not asked of participants to Q2, as it was assumed that most of these participants 
would have already had a DEXA scan as part of their routine care pathway). Three-quarters of 
all participants (75%) were prepared to have their own bone marrow extracted for the treatment, 
while 73% of all participants were prepared to have more than one site treated at a time.  
When disaggregating responses to the question regarding acceptability of bone marrow 
extraction between those participants with an osteoporosis diagnosis who had experienced a 
fracture and those with osteoporosis but who had not yet experienced an osteoporotic fracture, 
there was a trend towards the former group providing slightly more positive responses than the 
latter (Fig. 3). This might suggest that the experience of having an osteoporotic fracture may 
encourage a less risk averse attitude towards the treatment. 
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Figure 3: Bone marrow extraction split from participants who had (and had not) experienced 
bone fracture. 
When the participants were asked about the risk of fracture reduction they would expect the 
new treatment to provide, 42% of all participants stated that they would accept the treatment 
whatever the reduction in their risk of fracture would be. Whilst 11% of participants would 
only accept the treatment if it reduced their risk completely. 32% of participants said that they 
would only accept the treatment if it reduced their risk by half. When further exploring of the 
answers between participants with osteoporosis who had experienced an osteoporotic fracture 
and those who had not, there was a slight trend for the former group to give more positive 
responses than the latter (Fig. 4). 
 
Figure 4: Responses to reduction in risk of fracture expected from the proposed treatment. 
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The differences highlighted in Fig. 4 may suggest a frustration with existing treatments and 
their efficacy, or the ability of participants to tolerate existing treatment regimes, and the desire 
to try something quite new different. This theme of a willingness to try anything that could 
make a difference was apparent in the free text responses within both versions of the 
questionnaire.  
A high proportion of all participants (69%) stated that they would accept the proposed 
treatment if it reduced their risk of fracture, even if it did not improve their quality of life. For 
example, 73% of all participants said they would accept the proposed treatment it if reduced 
their risk of fracture and still required them to take their existing medication. Whilst, 68% of 
all participants said they would accept the proposed treatment if it reduced their risk of fracture 
but did not reduce pain. 
Again, differences were observed in the responses between those with osteoporosis who had 
experienced a fracture and those with osteoporosis who had not experienced a fracture, with 
the former group more likely to find the treatment acceptable regardless of reduction in pain or 
medication and improvements in quality of life as shown (Fig. 5-7). 
 
 
Figure 5: Response to reduction in ‘Risk of Fracture’ even if it did not improve quality of 
life. 
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Figure 6: Participants response to reduction in ‘Risk of Fracture’ even if required 
continuation of existing medication. 
 
 
Figure 7: Participants response to reduction in ‘Risk of Fracture’ even without any reduction 
to pain. 
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70% of participants also stated they would be prepared to have the treatment if it required 
repeating once a year, with 35% of participants stating they would be prepared to have the 
treatment every six months, if necessary. 
 
Findings from Focus Groups 
Three focus groups were undertaken with a total of 47 participants across the three groups. 
Two groups were held in Birmingham:  
1. With Elders having either African and/or Caribbean heritage 
2. One group was held in Leicester with Elders from the Asian community. Each focus 
group lasted between 60-90 minutes. Of the 47 participants, only two had personal 
experience of osteoporosis, though others knew friends or family members who had 
experienced the disease. 
Although the experience of having osteoporosis was limited amongst the focus group 
participants, the discussion within the groups raised similar themes as those raised by 
questionnaire participants in free text responses. These related to the nature of the biomaterial 
to be used, the likely effectiveness of the treatment balanced against the risk, the pain of the 
procedure, and the use of donor stem cells.  
The idea of an injectable biomaterial treatment into their body, articulated by some focus group 
participants as man-made foreign objects, made a number of participants feel uneasy. A 
difference was articulated between having a foreign object introduced into their body for a life-
saving purpose i.e., a pacemaker, and having one introduced for a purpose which might be 
considered to be improving quality of life, rather than saving life; with the former circumstance 
being more acceptable than the latter.  
Some focus group participants suggested that they wouldn’t want to tempt fate by having a 
procedure which could leave them worse off than they were before. A small number of 
participants thought that the procedure sounded painful and expressed the opinion that they 
would probably only consider the proposed treatment if they were experiencing a lot of pain 
that was interfering with their day-to-day lives, and were therefore willing to try anything to 
gain some relief.  
The use of stem cells in the proposed treatment also generated a good debate within the groups. 
Participants were aware that stem cell treatments were being used in other areas of medicine 
and were generally not concerned about the possibility of using donor stem cells, though some 
participants with stronger religious views felt that this was a more uncomfortable prospect. The 
possibility of the body rejecting donor stem cells was raised and it was questioned whether 
osteoporosis was an ‘important’ enough condition to risk potential clinical consequences of 
stem cell rejection, unlike a life-saving treatment like a heart transplant or kidney transplant. A 
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preference for autologous stem cells was expressed by a number of participants and if that was 
not feasible, the option of a familial donor was preferred over a donor that was unknown to 
them. No-one within the focus groups expressed the opinion that they would definitely refuse 
the treatment on the grounds that the stem cells would come from a donor. Some quotes from 
the Focus Group participants have been highlighted below: 
 
Risk versus Benefits 
‘Don’t know if it’s worth going through all that pain unless it was proven it would work. Would 
it be a one-off treatment or would it have to be repeated. Worried about long term and how 
your body would accept the foreign body.’ (Questionnaire respondent free text response). 
‘I think it would depend on the benefit realised. If the treatment significantly improved my 
quality of life/pain etc. I would be prepared to have the treatment more frequently to maintain 
those benefits.’ (Questionnaire respondent free text response).  
‘The risk of fracture would need to be greatly reduced i.e., by 50% or more. I would prefer the 
treatment to reduce the need for medication and I would probably not undertake treatment if 
pain was still felt unless it greatly reduced risk of fracture.’ (Questionnaire respondent free text 
response). 
 
Use of Foreign Materials 
‘You know, because it’s not as if you're transferring cells that we generate anyway, you're 
transferring some foreign body into your body and it just rings alarm bells for me in that sense, 
from a religious point of view and not just a regular point of view.’ (Focus Group 1 Attendee). 
‘We’re tampering with cells, putting cells into materials, expecting them to degrade after 
however many days, what happens if it doesn’t? What happens if, you know, you have other 
issues that suddenly pop up in that area? (Focus Group 1 Attendee). 
 
Promoting Quality of Life Rather Than Life-Saving 
‘I suppose it’s just like if you needed another kidney and you had to have it from somebody 
else. It would be the same sort of reaction really. But to me is it important enough to warrant 
that. Kidneys, yes. Heart, yes. Breaking your bones and limiting breaking your bones, is it as 
important? And there are things like replacement hips and knees and whatever as a treatment, 
so why this? That’s my reaction. Why this?’ (Focus Group 1 Attendee). 
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Use of Autologous Stem Cells versus Donor Stem Cells 
‘Would be happy with stem cells from adults. Do not want any from human 
embryos.’(Questionnaire respondent). 
‘When I considered donor stem cells I immediately thought it would be better coming from my 
own body but having someone else go through the extraction could save my pain and 
discomfort!’ (Questionnaire respondent). 
 
Discussion 
One limitation of this study was that the responses to both versions of the questionnaire and 
comments from the focus group participants represent only U.K. based patient and public 
perceptions for the acceptability of a stem cell therapy intervention proposed as a prophylactic 
bone fracture prevention treatment. Other studies have shown that attitudes and perceptions of 
patients from other countries (i.e., U.S.) are morally acceptable. A further limitation of this 
study is that the above focus groups did not include members of the Chinese community.  
Three clear themes emerged from the findings of this study:  
1. The general acceptability of the proposed treatment 
2. Preferences between autologous versus allogenic stem cells  
3. Areas of interest or concern that future trials and studies should consider 
 
Acceptability of the Treatment 
The perceptions of participants who have osteoporosis and who have experienced an 
osteoporotic fracture towards the proposed treatment were particularly positive, suggesting a 
strong level of acceptability within this target group. There was a small difference when 
comparing findings from this cohort of participants to findings from those participants who did 
not have any lived experience of osteoporosis, with the former group having a greater 
inclination towards accepting the treatment than the latter. This was perhaps not surprising, as 
it was more difficult for participants to assess how they may respond in any given 
circumstances when they have not experienced osteoporosis related fractures or any of the 
circumstances and impact it could have on their lives.  
The responses from participants regarding their acceptance of the treatment regardless of the 
extent to which it reduced their pain, improved their quality of life, or enabled them to stop 
taking current medication was particularly encouraging in their level of positivity. The small 
differences in responses between participants who had experienced an osteoporotic fracture 
and those who had not were also worthy of note. Osteoporosis is sometimes referred to as a 
‘silent disease’ as gradual bone loss and increasing fracture risk is not generally experienced 
as a painful process by some individuals. Many participants therefore do not start to feel pain 
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from their osteoporosis until they experience an osteoporotic fracture. It is therefore quite 
probable that having once experienced the pain of an osteoporotic fracture, participants accept 
that they will live with some residual pain but are very keen to avoid that pain worsening as a 
result of experiencing further fractures.  
A number of focus group participants expressed the opinion that they would consider the 
proposed treatment if they were experiencing a lot of pain that was interfering with their day-
to-day lives. They felt that the trade-off between the risks and potentially painful nature of the 
treatment and its likely benefit was worthwhile. The degree of pain that can be tolerated by 
participants is highly individualistic and this therefore makes an assessment of the outcome of 
the pain/gain decision at the individual patient level highly problematic [26].  
Regarding the potentially painful nature of the procedure itself, iliac crest aspiration procedures 
are certainly not pain free. These procedures require good technical skills in order to obtain 
samples suitable for processing and for reducing the pain associated with the procedure, which 
if poorly handled, could result in cancellation of the procedure. Furthermore, the type and 
calibre of the needles used are the main variables in this technique, the selection of which 
would depend on the patient’s age, gender and body mass index [27]. As such it is imperative 
that new treatments developed remain as minimally invasive as possible. 
Other reservations expressed by questionnaire participants and focus group participants were 
regarding the injection of the biomaterial construct, expressed by some as ‘man-made foreign 
objects’ - into the body. Though the use of in-vivo man-made objects within medicine is 
relatively commonplace i.e., pacemakers, joint replacements, breast implants etc. these are 
nonetheless legitimate concerns which would need to be addressed with clear, transparent 
patient information demonstrating how the biomaterials had been subject to stringent testing 
against regulatory standards, to demonstrate their safety. It is also possible that there will be 
some greater reluctance towards the treatment from those individuals who hold particularly 
strong religious views.  
Articulating the concept of risk to patients and helping them weigh up the pros and cons of 
receiving any particular treatment is a challenging exercise, specifically when it comes to a 
preventive rather than a curative treatment. In this case, patients would be weighing up the 
potential risks of having the procedure i.e., pain, adverse reactions to drugs etc., against the 
potential personal benefits of the proposed treatment i.e., a reduction in risk of fracture, 
potentially without any other benefits such as improved mobility, or a better quality of life. A 
number of focus group participants and questionnaire participants expressed the view that they 
wouldn’t want to ‘tempt fate’ by having a procedure that may leave them worse off than they 
were before. These comments may reflect the fact that for some participants, osteoporosis is 
not manifest e.g. they have no visible signs or symptoms of the disease and feel healthy, and 
therefore cannot assess the proposed treatment as being of benefit. 
This attitude was perhaps an indication of what is known in psychological terms as “loss 
aversion” [28]. This principle asserts that the impact of loss on individuals is felt more strongly 
than the impact of gain. If participants have osteoporosis but do not experience any symptoms 
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from the disease, the potential loss of being asymptomatic as a result of a painful procedure 
where there is always a risk of some complication occurring, however small, would be felt 
more keenly, than the potential benefit of reducing their later risk of an osteoporotic fracture.  
Hip and vertebral fractures, in addition to their obvious morbidity, also have a significant 
mortality rate [29,30]. The mobility and independence for patients having suffered hip or 
vertebral fractures, is often greatly reduced post fracture, resulting in higher societal costs than 
other common causes of prolonged hospitalisation such as cardiovascular disease, due to 
additional factors such as sarcopenia and poor quality of life [30]. Thus, effective prevention 
of bone fractures is not only vital for healthy aging, but must be considered as a potential 
option, especially as the elderly population increased. 
 
Preferences between Autologous versus Allogenic Stem Cells 
The use of autologous stem cells combined with the orthobiologic biomaterial (calcium 
phosphate porous microsphere material) for the proposed treatment, was not ruled out and it 
was particularly encouraging that questionnaire participants and focus group participants were 
not generally concerned about the possibility of using donor stem cells.  
The main concern from those that did express some hesitation was based on the chance of the 
body rejecting donor stem cells and for some osteoporosis was not considered a severe enough 
disease to risk potential clinical consequences of stem cell rejection, unlike heart failure or 
kidney failure for example. It is worth noting however that these views were expressed by 
participants who had no lived experience of osteoporosis and were therefore likely to be 
unaware of the potential consequences of the disease (i.e., the fact that more than half of 
patients suffering a hip fracture can no longer live independently and that over a quarter die 
within 12 months of the fracture) [29].  
This lack of awareness regarding the potential severity of the disease also led to some 
comments questioning the morality of using donor stem cells (considered by participants to be 
a limited resource), for a ‘non-life-threatening condition’. In reality, several research groups 
and companies are heavily investigating (and investing) in stem-cell scale-up manufacture. 
According to the latest review report published by the Cell and Gene Therapy Catapult, the 
network of GMP cell manufacturing facilities had doubled from 11 to 22 in five years, whilst 
the number of clinical trials the network facilities supported, had increased by 180% over the 
same period, from 21 in 2012 to 59 in 2017 [31]. The general public were likely to be 
completely unaware of this development however and perceptions of stem cells as a limited 
resource are likely to continue without a deliberate effort to inform participants.  
There was also an appetite among questionnaire participants and focus group participants to 
explore the feasibility of having familial donors for stem cell harvesting. However, the 
practicalities of familial donors at this early stage in the development of bio banking would 
need to be carefully considered as this could place additional processes within the treatment 
pathway [32]. Over time however, it is anticipated that bio banking facilities would enable 
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families to deposit stem cells for future use for a range of treatments for family members to 
utilise. 
 
Future Trials and Studies  
The level of knowledge regarding osteoporosis as a debilitating disease which can lead to an 
increased risk of mortality, is likely to be low among the general public. This was reflected in 
the responses of focus group participants and questionnaire participants without osteoporosis 
within this study. Even amongst those diagnosed with osteoporosis, the manifestation of the 
disease would likely affect participants’ conceptions of disease severity and risk of progression. 
Raising greater awareness of the disease amongst the general public and patients is therefore 
likely to be an important element of any future study, in order to increase an appreciation of 
the worth of the research and to subsequently encourage participation in future clinical studies.  
Whilst the proposed treatment to be developed would remain as minimally invasive as possible, 
the understandable concerns that participants would have regarding the potentially painful 
nature of the procedure, whether using autologous or allogenic stem cells, and the potential 
requirement for a general anaesthetic to be administered, would also need to be addressed 
openly. Clear, transparent patient information would help to ensure that future research 
participants were fully aware of the implications of their involvement. Information regarding 
the potential treatment should also attempt to address the ‘’loss aversion’’ principle by setting 
out the risks of the treatment against the potentially significant consequences of having an 
osteoporotic fracture, particularly of the hip and spine.  
Patient information should also clearly explain how the biomaterial had been approved for use 
as a medical device. It was possible that some patients who held strong religious beliefs may 
find the idea of a man-made material being introduced into their body in this way less palatable 
and this may potentially deter some patients from accepting the treatment. Though this may 
only affect a relatively small proportion of the population that could benefit from this treatment, 
it was important that healthcare professionals understood these concerns and addressed them 
clearly and transparently as they arose.  
The practicalities of introducing familial donors into the treatment pathway during clinical 
studies could also be explored, in order to test the feasibility of this option in routine practice. 
However, clearly discussing the source of the stem cells to be used in clinical trials, would be 
highly advantageous and would raise greater public and patient awareness of the developments 
in stem-cell manufacturing. This would potentially pre-empt any concerns participants may 
have regarding the use of limited stem cell resources for ‘non-life threatening’ conditions. 
 
Conclusion  
The proposed orthobiologic (stem cell) treatment for the elderly osteoporotic population had 
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a high level of patient and public acceptably. 94% of questionnaire (Q1) participants were 
prepared to have a DEXA scan to assess eligibility for the treatment; whilst three-quarters of 
all questionnaire participants (75%) were prepared to have their own bone marrow extracted 
for the treatment; 42% of participants stated they would accept the treatment whatever the 
reduction in their risk of fracture, while only 11% would accept the treatment if it reduced 
their risk completely. A high proportion of participants (69%) stated that they would accept 
the proposed treatment if it reduced their risk of fracture but did not improve quality of life, 
while 73% of said they would accept the proposed treatment it if reduced their risk of fracture 
and yet still required them to take their existing medication. Also, 68% of the participants 
stated they would accept the proposed treatment if it reduced their risk of fracture even if 
there was no reduction in pain.  
A few of the focus group participants did not have any experience of osteoporosis and were 
therefore commenting on a theoretical scenario which may have accounted for the more 
conservative nature of their responses. Concerns raised through the groups focused on the 
potential pain of the procedure, the risk of the procedure rendering the patient in a worse 
condition than before, and the nature of the injected material. Focus group participants 
generally felt they would have to be experiencing a degree of pain that was interfering with 
their day-to-day lives, in order to be prepared to try this kind of procedure. This was consistent 
with the questionnaire findings which suggested that the experience of having an osteoporotic 
fracture may encourage a less risk averse attitude towards the proposed treatment, perhaps as 
current treatments were reported as being of variable effectiveness.  
The findings presented here therefore demonstrate a clear mandate to the research team and 
community to continue their efforts in developing new proposed treatments for fracture 
prevention strategies. 
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